RU2016102143A - Композиция для предупреждения или лечения заболеваний почек, содержащая ингибитор dpp-iv - Google Patents
Композиция для предупреждения или лечения заболеваний почек, содержащая ингибитор dpp-iv Download PDFInfo
- Publication number
- RU2016102143A RU2016102143A RU2016102143A RU2016102143A RU2016102143A RU 2016102143 A RU2016102143 A RU 2016102143A RU 2016102143 A RU2016102143 A RU 2016102143A RU 2016102143 A RU2016102143 A RU 2016102143A RU 2016102143 A RU2016102143 A RU 2016102143A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- pharmaceutical composition
- composition according
- kidney disease
- pharmaceutically acceptable
- Prior art date
Links
- 208000017169 kidney disease Diseases 0.000 title claims 5
- 239000003112 inhibitor Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 229940125708 antidiabetic agent Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- KBINHYOGLICIMS-UHFFFAOYSA-N 2-hydroxyethanesulfinic acid Chemical compound OCCS(O)=O KBINHYOGLICIMS-UHFFFAOYSA-N 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 claims 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 239000000174 gluconic acid Substances 0.000 claims 1
- 235000012208 gluconic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 229960002510 mandelic acid Drugs 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 235000019161 pantothenic acid Nutrition 0.000 claims 1
- 150000002948 pantothenic acids Chemical class 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. Фармацевтическая композиция для предупреждения или лечения заболеваний почек, включающая соединение, представленное химической формулой 1, приведенной ниже; его оптический изомер; его фармацевтически приемлемые соли; или его гидрат или сольват
в которой X обозначает OR1, и R1 обозначает C1-C5 низшую алкильную группу, соответственно, в качестве активных ингредиентов.
2. Фармацевтическая композиция по п.1, в которой R1 обозначает трет-бутил.
3. Фармацевтическая композиция по п.1, в которой фармацевтически приемлемая соль выбрана из группы, состоящей из уксусной кислоты, бензолсульфоновой кислоты, бензойной кислоты, камфорсульфоновой кислоты, лимонной кислоты, этансульфоновой кислоты, фумаровой кислоты, глюконовой кислоты, глутаминовой кислоты, бромистоводородной кислоты, соляной кислоты, изэтиновой кислоты, молочной кислоты, малеиновой кислоты, яблочной кислоты, миндальной кислоты, метансульфоновой кислоты, муциновой кислоты, азотной кислоты, памовой кислоты, пантотеновой кислоты, фосфорной кислоты, янтарной кислоты, серной кислоты, винной кислоты, п-толуолсульфоновой кислоты и адипиновой кислоты.
4. Фармацевтическая композиция по п.1, в которой соединение, представленное химической формулой 1; его оптический изомер; его фармацевтически приемлемые соли; или его гидрат или сольват являются ингибиторами DPP-IV (дипептидил пептидазы-IV).
5. Фармацевтическая композиция по п.1, дополнительно содержащая другие антидиабетические средства.
6. Фармацевтическая композиция по п.1, в которой антидиабетические средства выбраны из группы, состоящей из бигуанида, сенсибилизатора инсулина, средства, усиливающего секрецию инсулина, ингибитора α-глюкозидазы и антагониста каннабиноидного рецептора 1.
7. Фармацевтическая композиция по п.1, дополнительно содержащая ингибитор ангиотензинпревращающего фермента или блокатор рецептора ангиотензина II.
8. Фармацевтическая композиция по п.1, где заболевание почек является гломерулярным заболеванием почек.
9. Фармацевтическая композиция по п.1, где заболевание почек является диабетическим заболеванием почек.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130073711 | 2013-06-26 | ||
| KR10-2013-0073711 | 2013-06-26 | ||
| PCT/KR2014/005302 WO2014208921A1 (ko) | 2013-06-26 | 2014-06-17 | Dpp-iv 저해제를 함유하는 신장 질환 예방 또는 치료용 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016102143A true RU2016102143A (ru) | 2017-07-31 |
| RU2652343C2 RU2652343C2 (ru) | 2018-04-25 |
Family
ID=52142202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102143A RU2652343C2 (ru) | 2013-06-26 | 2014-06-17 | Композиция для предупреждения или лечения заболеваний почек, содержащая ингибитор dpp-iv |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10159667B2 (ru) |
| EP (1) | EP3015106B1 (ru) |
| JP (1) | JP6352411B2 (ru) |
| KR (1) | KR101626653B1 (ru) |
| CN (1) | CN105555275B (ru) |
| AU (1) | AU2014299575B9 (ru) |
| BR (1) | BR112015032410B8 (ru) |
| CA (1) | CA2916698C (ru) |
| ES (1) | ES2884815T3 (ru) |
| HU (1) | HUE055812T2 (ru) |
| MX (1) | MX2015017956A (ru) |
| NZ (1) | NZ715573A (ru) |
| PT (1) | PT3015106T (ru) |
| RU (1) | RU2652343C2 (ru) |
| WO (1) | WO2014208921A1 (ru) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002335843A1 (en) * | 2001-10-17 | 2003-04-28 | King Pharmaceuticals Research And Development, Inc | Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| KR20050016452A (ko) | 2002-05-29 | 2005-02-21 | 노파르티스 아게 | Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물 |
| KR20120008093A (ko) | 2003-11-17 | 2012-01-25 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| CN101229373B (zh) * | 2007-01-26 | 2010-09-15 | 鲁南制药集团股份有限公司 | 治疗糖尿病肾病的药物组合物 |
| CN102516184B (zh) | 2007-04-19 | 2015-03-25 | 东亚St株式会社 | 包含β-氨基的DPP-IV抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 |
| KR101054911B1 (ko) * | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
-
2014
- 2014-06-17 KR KR1020140073388A patent/KR101626653B1/ko active IP Right Grant
- 2014-06-17 WO PCT/KR2014/005302 patent/WO2014208921A1/ko active Application Filing
- 2014-06-17 MX MX2015017956A patent/MX2015017956A/es unknown
- 2014-06-17 US US14/392,160 patent/US10159667B2/en active Active
- 2014-06-17 CA CA2916698A patent/CA2916698C/en active Active
- 2014-06-17 JP JP2016523630A patent/JP6352411B2/ja active Active
- 2014-06-17 RU RU2016102143A patent/RU2652343C2/ru active
- 2014-06-17 HU HUE14817709A patent/HUE055812T2/hu unknown
- 2014-06-17 PT PT148177090T patent/PT3015106T/pt unknown
- 2014-06-17 EP EP14817709.0A patent/EP3015106B1/en active Active
- 2014-06-17 ES ES14817709T patent/ES2884815T3/es active Active
- 2014-06-17 CN CN201480045577.2A patent/CN105555275B/zh active Active
- 2014-06-17 BR BR112015032410A patent/BR112015032410B8/pt active IP Right Grant
- 2014-06-17 AU AU2014299575A patent/AU2014299575B9/en active Active
- 2014-06-17 NZ NZ715573A patent/NZ715573A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015017956A (es) | 2017-02-13 |
| KR20150001628A (ko) | 2015-01-06 |
| AU2014299575A1 (en) | 2016-01-28 |
| US20160184300A1 (en) | 2016-06-30 |
| CA2916698C (en) | 2021-03-09 |
| RU2652343C2 (ru) | 2018-04-25 |
| EP3015106A4 (en) | 2017-01-04 |
| CA2916698A1 (en) | 2014-12-31 |
| JP6352411B2 (ja) | 2018-07-04 |
| BR112015032410B1 (pt) | 2020-12-29 |
| BR112015032410B8 (pt) | 2021-10-26 |
| AU2014299575B2 (en) | 2017-07-27 |
| EP3015106B1 (en) | 2021-08-11 |
| ES2884815T3 (es) | 2021-12-13 |
| EP3015106A1 (en) | 2016-05-04 |
| NZ715573A (en) | 2017-08-25 |
| PT3015106T (pt) | 2021-09-06 |
| CN105555275B (zh) | 2021-04-20 |
| HUE055812T2 (hu) | 2021-12-28 |
| US10159667B2 (en) | 2018-12-25 |
| WO2014208921A1 (ko) | 2014-12-31 |
| KR101626653B1 (ko) | 2016-06-01 |
| AU2014299575B9 (en) | 2017-08-17 |
| CN105555275A (zh) | 2016-05-04 |
| JP2016526555A (ja) | 2016-09-05 |
| BR112015032410A2 (pt) | 2017-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| CO6290644A2 (es) | Antagonista del receptor opioide selectivo kappa. | |
| WO2012101065A3 (en) | Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors | |
| JO2894B1 (en) | Salt and new amorphous images | |
| NO20084318L (no) | Inhibitorer av II-beta-hydroksystereoid dehydrogenase I | |
| UA107174C2 (uk) | Кристалічні форми саксагліптину та процес їх одержання (варіанти) | |
| RU2582676C3 (ru) | Некоторые химические соединения, композиции и способы | |
| EA201270646A1 (ru) | Ингибиторы глюкозилцерамидсинтазы | |
| NZ610104A (en) | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| JP2008533007A5 (ru) | ||
| PE20060011A1 (es) | COMPUESTOS AMIDAS DE ACIDOS CARBOXILICOS COMO INHIBIDORES DEL FACTOR Xa | |
| MX2007011083A (es) | Formas cristalinas de un compuesto bifenilo. | |
| MX361488B (es) | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk). | |
| EA201200763A1 (ru) | Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep | |
| CU24000B1 (es) | Un derivado 2-carboxamida-cicloamino-urea-tiazol-piridilo | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| RU2017109814A (ru) | Кристаллическая 7-{ (3s,4s)-3-[(циклопропиламино)метил]-4-фторпирролидин-1-ил} -6-фтор-1-(2-фторэтил)-8-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота | |
| EA201070635A1 (ru) | Соединения, ингибирующие дипептидилпептидазу-iv,способы их получения и фармацевтические композиции, содержащие их в качестве активного агента | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| EA201691538A1 (ru) | Способ получения солей вортиоксетина | |
| EA022994B1 (ru) | Способ подавления толерантности к опиоидному анальгетику | |
| EA201071269A1 (ru) | 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина | |
| NZ592543A (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| PE20142244A1 (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina |